Stanford University

Business

Announcing the Asia-Pacific Health Policy Forum

Authors
Karen Eggleston
News Type
News
Date
Paragraphs

The Asia Health Policy Program of the Shorenstein Asia-Pacific Research Center invites scholars from multiple disciplines to join the Asia-Pacific Health Policy Forum (APHPF) by creating your own account on our website.  Your information will be saved in our online database, searchable by name, country or region of focus, discipline, and topic.  

The mission of the Asia-Pacific Health Policy Forum (APHPF) is to serve as a resource for social science research, teaching, and evidence-based policymaking about health and healthcare in the Asia-Pacific region. 

Specifically, APHPF aims to

  • encourage collaboration among social scientists doing research on health policy in the Asia-Pacific region;
  • serve as a resource for teaching about health and healthcare in specific countries and regions within the Asia-Pacific;
  • provide analysis to inform policy, by offering a forum for rapid dissemination of policy-relevant research results, as well as by linking organizations, programs, conferences and white papers about specific health policy issues; and
  • raise awareness and foster dialogue among researchers, policymakers, and business about cross-cutting themes and global challenges of health and healthcare access, quality, and cost, within the specific historical and cultural contexts of the diverse nations of the Asia-Pacific. 

We encourage all researchers with an interest in health and healthcare in the Asia-Pacific to create an account and to submit information about upcoming conferences and sessions within larger disciplinary conferences that focus on any aspect of health policy in the Asia-Pacific to the Forum coordinator, Karen Eggleston. 

There are no membership dues, as the Forum is currently supported by the Asian Health Policy Program of the Shorenstein Asia-Pacific Research Center at Stanford University.

The Asia-Pacific Health Policy Forum represents a multidisciplinary effort to build organizational linkages and work toward developing an Asia-Pacific parallel to the European Observatory on Health Systems and Policy.

With your help, the APHPF can develop into a vibrant resource and networking support for all of us seeking to understand and improve health and healthcare systems in the region.

All News button
1

Hidden Alliance: While the West Hears Only a Cacophony of Mutual Recriminations, Beijing and Tokyo are Quietly Making Sweet Music Together

-

Conventional wisdom says that relations between China and Japan are fated always to be exceptionally wary, if not openly hostile -- and Japanese leaders' visits to the notorious Yasukuni have done nothing to undermine this view. Nor have Sino-Japanese standoffs over the disputed Senkaku islands. Meanwhile Beijing's opposition has been widely credited as the reason why Japan has failed in its reported aspiration to join the United Nations Security Council. Author and long-time Tokyo-based East Asia watcher Eamonn Fingleton argues that these issues have been grossly misunderstood in the West and that on closer inspection they say little if anything about the true state of Sino-Japanese relations. He insists that on a host of substantive issues overlooked by the press, Japan and China have been cooperating closely for decades. So much so that Japanese help has been one of the most powerful factors in China's rise.

A former editor for Forbes and the Financial Times, Eamonn Fingleton has been monitoring East Asian economics since 1985. He met China's supreme leader Deng Xiaoping in 1986 as a member of a New York Stock Exchange delegation. The following year he predicted the Tokyo banking crash and went on in Blindside, a controversial 1995 analysis that was praised by J.K. Galbraith and Bill Clinton, to show that a heedless America was fast losing its formerly vaunted leadership in advanced manufacturing to Japan.

His 1999 book In Praise of Hard Industries: Why Manufacturing, Not the Information Economy, Is the Key to Future Prosperity anticipated the American Internet stock crash of 2000. In his 2008 book In the Jaws of the Dragon: America's Fate in the Coming Era of Chinese Hegemony, he issues a strong challenge to the conventional view among Washington policymakers and think tank analysts that China is converging to Western economic and political forms and attitudes. His books have been read into the U.S. Senate record and named among the ten best business books of the year by Business Week and Amazon.com.

He was born in Ireland in 1948 and is a graduate of Trinity College Dublin. He was the recipient of the American Values Award from the United States Business and Industry Council in 2001.

Copies of Fingleton's newest book In the Jaws of the Dragon: America's Fate in the Coming Era of Chinese Hegemony - due March 4 by St. Martin's Press - will be for sale during the event.

Philippines Conference Room

Eamonn Fingleton author Speaker
Seminars

Why only Nintendo?--Challenges Facing the Japanese Software Industry

-
Every day you drive your Toyota Prius to work; when you return home you watch a Sony television, and your DVD player has a laser semiconductor produced by Mitsubishi. On weekends you take pictures with a Canon digital camera.

Everyone knows that the market is filled with Japanese high-tech products. You might, however, not realize that with the exception of the one running on your game console, you probably have never seen a Japanese software product.

In this seminar, Dr. Fushimi will present his analysis on why the Japanese have been so weak in the global software market. He will first discuss the intrinsic differences between software and hardware, and use these differences as a framework to identify the critical mistakes Japanese software companies have made.

Shinya Fushimi has spent twenty years in the Japanese IT industry, serving various R&D and management positions. Most recently, he was Head of Data Centric Solution Business Unit of Mitsubishi Electric. He received the BS, MS, and PhD in computer science from The University of Tokyo and has received a number of academic awards like the Moto-oka Memorial Prize and Best Paper Award for a Young Researcher. Prior to joining Shorenstein APARC, he was with the Sloan Master's Program of Graduate School of Business, Stanford University, and received the Master of Science in Management.

Download pdf

Philippines Conference Room

Shinya Fushimi

0
Corporate Affiliate Visiting Fellow
Shinya.jpg MS, PhD

Shinya Fushimi is a corporate affiliate visiting fellow at Shorenstein APARC for 2007-2008. A 20-year IT industry veteran, Fushimi started his career as a researcher of Mitsubishi Electric Corporation, Tokyo, Japan, and developed various innovative products. One of his products, a hardware sorting engine, made a new world record of data sorting performance in 2000. He then served various management positions in R&D, sales, marketing, and engineering. Most recently, he was Head of Data Centric Solution Business Unit of Mitsubishi Electric. The unit has developed more than 1,000 new customers.

He received BS, MS, and Ph.D in computer science from The University of Tokyo. Prior to joining Shorenstein APARC, he was with the Sloan Master's Program of Graduate School of Business, Stanford University, and received a master's degree in business management.

He received a Moto-oka Memorial Prize, a Best Paper Award for Young Researcher of Information Processing Society of Japan, Mitsubishi Electric's President Award, and Best Patent Award. He holds 52 patents in Japan, US, Germany, France, UK, China, Taiwan, and Korea, and lectured on database technologies and IT business at various universities such as The University of Tokyo in Tokyo and Ewha Women's University in Seoul. He is the recipient of an IBM Pre-Doctoral Fellowship in 1983.

Hide publication sections
Off
Date Label
Shinya Fushimi Speaker
Seminars

2008 Year Ahead Part I: Japanese Society and Culture

-

Where is Japanese society and culture headed in the New Year? What social trends may shape Japan's future? From the latest pop culture developments to the changing Japanese attitude toward women and families, our panelists will provide an up-to-date view of Japanese society today and beyond.

Mariko Fujiwara is research director of Hakuhodo Institute of Life and Living (HILL). She is also a partner in the consultancy Business Futures Network (London), executive director of Mobile Marketing Inc., and serves on ministerial councils including the Ministry of Internal Affairs and Communications, Ministry of Finance, and the Supreme Court. She has published reports on Japanese consumers, Japan's post-war baby boom generation, second baby boom generation, changing roles of women and families, Japan's aging population and emerging trends among senior citizens.

Roland Kelts is the author of Japanamerica: How Japanese Pop Culture Has Invaded the U.S., published in the U.S., Europe, and Japan. He is a lecturer at the University of Tokyo, a columnist for The Daily Yomiyuri and an editor of the New York-based literary journal, A Public Space. His first novel, Access, will be published next year. His articles, essays, and stories have been published in Zoetrope; Playboy; Salon; DoubleTake; The Village Voice; Newsday; Cosmopolitan; Vogue; The Japan Times; among others.

Please visit events at www.usajapan.org or call 415-986-4383 for reservation.
2008 Year Ahead is made possible by the generous support of Union Bank of California

Delancey Screening Room
600 Embarcadero Street
San Francisco, CA 94107

Mariko Fujiwara Research Director Speaker Hakuhodo Institute of Life and Living
Roland Kelts author and journalist Speaker
Conferences

Early-Stage Valuation in the Biotechnology Industry

Paragraphs

Biotechnology (or biotech) has impacted almost every aspect of human life. It has reorganized industries, drastically changed healthcare, helped to improve the environment, and led to important changes in laws and ethical norms.

Among the various biotech fields, medical biotech has been by far the most influential, beneficial, and controversial. It has generated not only superlative discoveries to improve the lifespan and quality of human life, but also the greatest amount of wealth for all the players involved, and the greatest volume of public debate.

Several important trends are shaping the future of the pharmaceutical (or pharma) and biotech industries. The biotech industry is characterized by the presence of strong clusters in all countries. The pharma and biotech industries are experiencing an outsourcing phenomenon, mainly due to a lack of in-house expertise and efficiencies. Diagnostics and therapeutics are increasingly converging, a trend that will lead to predictive and precise diagnostics and personalized and preventive medicine. The first few years of the twenty-first century have witnessed significant changes in the pharma/biotech alliance landscape. Today we are seeing the “omic”-ization of the biotech industry: most of the emerging technologies are genomics, proteomics, cellomics, and pharmacogenomics. In addition, the biotech industry faces uphill ethical issues, including excessive marketing, third-world drug availability, genetic engineering, stem cells, and cloning.

The medical biotech industry faces several challenges. First, science, the human body, and disease are, essentially, complex. Second, unlike other high-technology industries, the biotech product development cycle is very long, even after proof of concept. Biotech projects take between ten and twenty years to become successful and cost over $200–300 million before a product reaches the market. Third, delivery of most biotech products and therapies is complex and can be painful, often involving intravenous delivery. Fourth, the preceding three factors pose significant challenges for research and development (R&D) financing. In addition, there are certain outside determinants that influence the biotech industry, including regulation, demography, reimbursement climate, and big pharma companies.

Stem cell research is one of the most fascinating areas of biology, but it raises questions as rapidly as it generates new discoveries. The greatest potential application of this research is the generation of cells and tissues that can be used for cell-based therapies. A stem cell is a special kind of cell that has a unique capacity to renew itself and to give rise to specialized cell types. Through the process of differentiation, stem cells form various tissues and organs, and the combination of these differentiated materials develops into the whole human body. This class of human stem cell holds the promise of being able to repair or replace cells or tissues that are damaged or destroyed by many of our most devastating diseases.

Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes mellitus is a type I diabetes—also called juvenile-onset diabetes or insulin-dependent diabetes—and develops when the body’s immune system destroys pancreatic beta cells, the only cells in the body that make the insulin that regulates blood glucose. Type II diabetes, also called adult-onset diabetes or noninsulin-dependent diabetes, may account for 90–95 percent of all diagnosed cases of diabetes. There are more than 194 million diabetics worldwide, with this number expected to exceed 333 million by 2025.

Insulin is currently the most effective drug for controlling hyperglycemia and is widely accepted as the gold standard for treating type I diabetes and even late-stage type II diabetes. However, physicians and patients are reluctant to use insulin until other less effective drugs have been attempted. This is mainly because insulin therapy is invasive and painful: patients must take insulin intravenously.

One of the most promising ways to cure diabetes is to restore the function of islet cells biologically, either through islet cell transplantation or by engineering cells to restore the insulin secreting function. Islet transplantation, a procedure that can restore insulin production in patients, is a highly promising area of research.

Based on analysis of stem cell research, diabetes market opportunities, and the development of stem cell therapies, it is possible to place a value on a company in the early (preclinical) development stage of a stem cell therapy for diabetes. Such an exercise involves valuing a company based on three different approaches—(1) the discounted cashflow model, (2) the royalty or licensing model, and (3) the comparables valuation model. Sensitivity analysis based on market, pricing, costing, R&D, and development stage can further lead to precise valuation range for a given company.

For biotechnology companies, various drivers play a critical role in company valuation, including people (management team), alliances and partnerships, intellectual property rights, R&D and technology, funding and financing, market opportunity, and therapeutic area.

All Publications button
1
Publication Type
Working Papers
Publication Date
Journal Publisher
Shorenstein APARC
Authors

Beyond Borders: Global Entrepreneurship

-

Up-and-coming Stanford entrepreneurs must think and act globally. Critical resources, markets and opportunities are around the world. Come meet three global entrepreneurs and hear how they got started, challenges they are wrestling with right now, and their best advice on going global.

SPRIE Co-Director Dr. William F. Miller will moderate a panel discussion featuring William A. Chen, Dr. Robert P. Lee, and Gadi Maier.

After the panel discussion there will be a question and answer period, followed by Chinese appetizers and networking.

This event, co-sponsored by the Asia-Pacific Student Entrepreneurship Society (ASES), is open to students, the Stanford community and the general public and is part of Entrepreneurship Week at Stanford University.

You can see the entire Entrepreneurship Week agenda at eweek.stanford.edu, including information about the Innovation Tournament for student teams.

About the panelists
William Chen: A General Partner with DT Capital Partners, Chen has been involved in technology companies and startups in Silicon Valley and China, most recently as Founder and CEO of Accelergy Corporation, a R&D technology company with operations in the US and Shanghai. Prior to Accelergy, Chen was Founder and CEO of OnePage, Inc., an enterprise software company that developed a suite of portal products and management tools for the corporate market (acquired by Sybase, Inc.). Before starting OnePage, he was one of the Founders of Billpoint, Inc., which pioneered the concept of online person to person payments. Chen has a BS from the University of Florida and a MBA from Harvard Business School.

Dr. Robert P. Lee: Lee, a 30-year veteran of the computer industry, is Chairman and CEO of Achievo Corporation, which he co-founded in 2002 while he served as president and CEO of Accela, Inc., a leading government automation software company. He was president and CEO of Inxight Software, Inc. before joining Achievo. Prior to that, he was Chairman, President and CEO of Insignia Solutions plc, a software company he took public in 1995. Dr. Lee has served as Executive VP at Symantec Corporation, and was Senior VP at Shared Medical Systems Corporation (now merged with Siemens). He received a BS from the University of California, Berkeley, and MS and PhD from the University of California, Los Angeles, all in computer science.

Gadi Maier: Most recently, Maier was CEO and President of Israel-based FraudSciences Corporation, (recently purchased by eBay), and prior to that he spent a year as Venture Partner at Pinnacle Ventures and Benchmark Capital. He was a co-founder and CEO of Scalent Systems (advanced datacenter virtualization software) and he co-founded Currenex, (a marketplace for buyers and sellers of foreign currency, sold to State Street Bank). Preceding Currenex, Maier was CEO, President and Chairman of GetThere, (on-line travel technology to corporations and airlines), leading GetThere's IPO as well as its sale in 2000 to Sabre Corporation. He has served as CEO for Memco Software, Inc., VP & General Manager for Cisco Systems' Internet Business Unit and held senior-level management positions at Oracle. Gadi holds a BS and MBA from the University of California, Berkeley.

Download pdf

Bechtel Conference Center

William F. Miller Moderator
William Chen General Partner Panelist DT Capital Partners
Dr. Robert P. Lee Chairman and CEO Panelist Achievo Corporation
Gadi Maier CEO and President Panelist FraudSciences Corporation
Conferences

John Hagel and Henry Chesbrough deliver keynote addresses at "The Shape of Things to Come" conference

Authors
George Krompacky
News Type
News
Date
Paragraphs

"The Shape of Things to Come," a conference presented by the Stanford Program on Regions of Innovation and Entrepreneurship on January 17-18, 2008, featured keynotes by John Hagel, co-author of The Only Sustainable Edge and Co-Chairman of the Deloitte Center for Edge Innovation, and Dr. Henry Chesbrough, Executive Director of the Center for Open Innovation at the Haas School of Business at UC Berkeley and author of Open Innovation.

The keynotes bookended Thursday's forum, "New Patterns and Paradigms in Global Innovation Networks," and were a prelude to Friday's academic workshop, "A Global Perspective on Regional Innovation Indicators." Hagel's talk focused on the need for a more explicit taxonomy of innovative collaboration and discussed the "huge need to define pragmatic migration paths"--routes that the average manager and company can take to reach the opportunities that normally are only accessible to cutting-edge companies.

The forum closed with a presentation by Dr. Henry Chesbrough, who provided an overview on the globalization of innovation in the Chinese semiconductor industry, which he sees as split into a "globally oriented, globally competitive" industry segment and a domestically-oriented segment with "backward technologies" and lacking access to capital. The question, he explained, is how China will shift its resources, now entrenched in the latter, to the former, competitive segment.

Chesbrough finished with a discussion of intellectual property rights (IPR) in China, looking at flows of knowledge and current IPR challenges; he mentioned some surprising developments--the rise of businesses to "promote the legal exchange of IP" and the growth of a domestic constituency for stronger IPR--and discussed future implications for IPR in China.

In between the keynotes, the forum featured sessions on innovation in internet services in China, the role of venture capital as a network builder, and discussions on two rapidly moving industries: cleantech and thin film transistor LCD displays.

Conference materials, including presentations and audio files, will be made available on the SPRIE website.

All News button
1
Subscribe to Business